A rational approach for the targeted discovery and characterisation of microbiome-derived therapeutics
Krause, L.; Boyd, J.; Vivian, C.; Krueger, A.; Jimenez Loayza, J.; Ljungberg, J.; Zhou, J.; Rabellino, A.; Nyeverecz, B.; Nissen, M.; Tousignant, K.; Bongers, M.; Cooper, M. M.; Parks, D. H.; Alsheikh, A.; Vera-Wolf, P.; Sullivan, M.; Newell, R.; Masterman, K.-A.; Evans, P.; Fang, L.; MacDonald, S.; Chuvochina, M.; Bessette, D.; Zimmermann, K.; Pribyl, A.; Chipperfield, H.; Caban, S.; McCarthy, H.; Soh, J.; Reid, L.; Frazer, I. H.; Angel, N.; Kenna, T.; Wood, D. L. A.; Wills, B.; Begun, J.; Keely, S.; Munro, T.; Tyson, G.; Hugenholtz, P.; O Cuiv, P.
Show abstract
The human gut microbiome is intrinsically involved in health and disease, representing a wealth of untapped therapeutic potential. Here, we demonstrate the utility and potential of a metagenome guided, large cohort-based approach for the rational selection of live biotherapeutics from the human gut. We applied this approach to Inflammatory Bowel Disease (IBD), identifying several lead candidates that were significantly depleted in individuals with IBD compared to healthy controls. Their therapeutic potential was assessed in preclinical models of IBD where they improved markers of disease pathology by reducing inflammation and promoting mucosal healing and wound repair. All leads had excellent safety profiles in silico and in vitro, and several additionally presented favourable manufacturing properties, supporting their progression into clinical trials. We believe that this rational approach will be generalisable to any disease state with underlying microbiome aetiology and will expedite the development of novel microbiome-derived therapeutics to improve human health.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Blood-borne immune cells carry low biomass DNA remnants of microbes in patients with colorectal cancer or inflammatory bowel disease 95%
- Fusobacterium sphaericum sp. nov., isolated from a human colon tumor, adheres to colonic epithelial cells and induces IL-8 secretion 95%
- Human gut commensal Alistipes timonensis modulates the host lipidome and delivers anti-inflammatory outer membrane vesicles to suppress colitis in an Il10-deficient mouse model 95%
Similar papers in this journal
- Biosynthetic Enzyme-guided Disease Correlation Connects Gut Microbial Metabolites Sulfonolipids to Inflammatory Bowel Disease Involving TLR4 Signaling 97%
- Impact of early life antibiotic and probiotic treatment on gut microbiome and resistome of very-low-birth-weight preterm infants 96%
- Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites 95%
Similar papers in this journal
- Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness 95%
- Prolonged Antibiotic Treatment Generates a Fluoroquinolone Resistant Gut Microbiome and Collateral Multi-Drug Resistance 94%
- Early-life microbial intervention reduces colitis risk promoted by antibiotic-induced gut dysbiosis 94%
Similar papers in this journal
- Transplantation of bacteriophages from ulcerative colitis patients shifts the gut bacteriome and exacerbates severity of DSS-colitis 96%
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia 95%
- Stratification of human gut microbiomes by succinotype is associated with inflammatory bowel disease status 94%